Neuraxpharm appoints Dr. Maximilian von Wülfing as COO

Neuraxpharm appoints commercial expert Dr. Maximilian von Wülfing as Chief Operating Officer

Europe’s leading CNS specialty company underpins strategy by reinforcing commercial structure with new COO role

Düsseldorf and Barcelona, June 1, 2021 – Neuraxpharm Group (Neuraxpharm), a leading European specialty pharmaceutical company focused on the central nervous system (CNS), announces today that Dr. Maximilian von Wülfing has been appointed Chief Operating Officer (COO), with effect from June 1, 2021. With the newly created COO position and the appointment of Dr. von Wülfing, Neuraxpharm strengthens its commercial leadership, underpinning its strategic focus as a leader in CNS.

Read more…

By Optimum

For more information about Optimum Strategic Communications, please get in touch

We'd love to hear from you...